Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-03-11
1995-09-05
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530350, C07K 1452, C07K 14435, A61K 3816
Patent
active
054479134
ABSTRACT:
Improved therapeutic uses of bactericidal/permeability-increasing protein (BPI) involve use of BPI protein product formulations in the form of physiologically stable dimeric associations of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by weight dimeric product.
REFERENCES:
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5348942 (1994-09-01), Little
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A.sub.2 from Rabbit Polymorphonuclear Leukocytes," Journal of Biological Chemistry, 254(21):11000-11009 (Nov. 10, 1979).
Elsbach et al., "Oxygen-Independent Antimicrobial Systems of Phagocytes" Inflammation: Basic Principles and Clinical Correlates, Second Edition, Chapter 30, 603-636 (1992).
Engleka et al., "Inactivation of Human Fibroblast Growth Factor-1 (FGF-1) Activity by Interaction with Copper Ions Involves FGF-1 Dimer Formation Induced by Copper-catalyzed Oxidation," Journal of Biological Chemistry, 267(16):11307-11315 (Jun. 5, 1992).
Folkman et al., Inflammation: Basic Principles and Clinical Correlates, 2d Ed. Chapter 40, pp. 821-839 (1992).
Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," Infection and Immunity, 60(1):4754-4761 (Nov. 1992).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," Journal of Biological Chemistry, 264(16):9505-9509 (Jun. 5, 1989).
Hartman et al., "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," PNAS USA, 85:8047-8051 (1988).
In't Veld et al., "Effects of Bactericidal/Permeability-Increasing Protein of Polymorphonuclear Leukocytes on Isolated Bacterial Cytoplasmic Membrane Vesicles," Infect. and Immun., 56:1203-1208 (1988).
Kozak, "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs," Nucl. Acids. Res., 15:8125 (1987).
Liu et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity," Journal of Immunology, 139(10):3521 (1987).
Mannion et al., "Separation of Sublethal and Lethal Effects of Polymorphonuclear Leukocytes on Escherichia coli," J. Clin. Invest., 86:631-641 (Aug. 1990).
Morrison et al., "Endotoxins And Disease Mechanisms," Ann. Rev. Med., 38:417-432 (1987).
Morrison, "The case for specific lipopolysaccharide receptors expressed on mammalian cells," Microb. Pathol., 7:389-398 (1989).
Mulligan et al., "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase," PNAS, USA, 78:2072-2076 (1981).
Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and A Newly Isolated 30kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," J. Exp. Med., 174:649-655 (Sep. 1991).
Passaniti et al., Methods in Laboratory Investigation, "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," Lab. Invest., 67:519-528 (1992).
Raetz et al., "Biochemistry of Endotoxins," Ann. Rev. Biochem., 59:129-170 (1990).
Roeder et al., "Endotoxic-Lipopolysaccharide-Specific Binding Proteins on Lymphoid Cells of Various Animal Species: Association with Endotoxin Susceptibility," Infect. and Immun., 57:1054-1058 (1989).
Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Harbor Press, 16.30-16.31 (1989).
Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," J. Mol. Appl. Gen., 1:327 (1982).
Weiss et al., "Resistance of Gram-negative Bacteria To Purified Bactericidal leukocyte Proteins," J. Clin. Invest., 65:619-628 (1980).
Weiss et al., "The Role Of Lipopolysaccharides In The Action Of The Bactericidal/Permeability-Increasing Neutrophil Protein On The Bacterial Envelope," Journal of Immunology, 132(6):3109-3115 (Jun. 1984).
Weiss et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," Blood, 69(2):652-659 (Feb. 1987).
Xu et al., "Transcription Termination and Chromatin Structure of the Active Immunoglobulin K Gene Locus," J. Biol. Chem., 261:3838 (1986).
Yayon et al., Cell, 64:841-848 (1991).
Ammons William S.
Little Roger G.
Jacobson Dian C.
Wax Robert A.
Xoma Corporation
LandOfFree
Therapeutic uses of bactericidal/permeability-increasing protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of bactericidal/permeability-increasing protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of bactericidal/permeability-increasing protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-472796